2011 Biotechnology Research Review

Published - Jan 2012| Analyst - Various Analysts| Code - BIO069C
Market Research Report Single User License: $475 Member Price: FREE

Report Highlights

  • The global market for sample preparation reagents and products used in life science research was $2.9 billion in 2010 and is expected to increase to $3.6 billion by 2011. The market is forecast to reach $8.4 billion by 2016, increasing at a compound annual growth rate (CAGR) of 18.8%.
  • The global biobanking market was $141 billion in 2010 and is projected to expand by 30% between 2010 and 2015, increasing at a CAGR of 5.4%.
  • The global RNAi drug delivery market was worth $7 billion in 2010 and is expected to grow to nearly $24.1 billion by 2015, increasing at a five-year CAGR of 27.9%.


During 2011 we witnessed the segmentation of the biotechnology industry as had long been forseen, drawn farther afield from its initial drug focus into areas such as “cleantech” and chemical manufacturing.

While American Recovery and Reinvestment Act (ARRA) funds helped foster drug research and development, we noticed surprising emphasis on low-possibility-of-success (POS) areas such as antineoplastic and immunomodulating agents, contrasting with smaller sums being sent into higher POS fields, such as acute diseases or dermatology.  This somewhat swinging-for-the-fences mentality has a rationale in that if successful these products have much lower post launch competition.  But if uncoupled to creative thinking at the R&D stage, one wonders what the ultimate ROI will be for taking this risk, and if patent expiration desperation is fueling this trend.  Perhaps significantly, the sports world has names and faces of major league pitchers who have gone ahead with stem cell treatments, with the hopes of resurrecting lucrative careers.  Mainstream acceptance of the risk involved in immature therapeutics surely paves the way for more clinical trials and regulatory urgency.

Regarding segmentation, we see many patents and venture capital dollars flowing into synthetic biology applications and “plants engineered to replace oil” efforts, such as algae biofuels and synthetic photosynthesis.  The term “Biobrick” has come into common usage and will certainly not fade anytime soon.

This Biotechnology Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since BCC was founded in 1971.  It includes highlights from the following reports published in 2011:

  • Polymerase Chain Reaction (PCR) Technologies and Global Markets
  • Biobanking: Technologies and Global Markets
  • Global Biochip Markets: Microarrays and Lab-on-a-Chip
  • Next-Generation Cancer Diagnostics: Technologies and Global Markets
  • RNAi Drug Delivery: Technologies and Global Markets
  • Stem Cell Therapeutics for Oncology: Technologies and Global Markets
  • Flow Cytometry: Products, Technologies and Global Markets
  • Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets

We hope you find this Research Review valuable, and we look forward to serving our customers’ biotechnology market research needs.

Chris Spivey

Senior Editor

BCC Research

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Oct-2010| Analyst - Various Analysts| Code - BIO069B

Report Highlights

  • Global sales of chiral technology products in 2008 were $4.3 billion and with 3.3% growth, the sales reached $4.5 billion in 2009. This market is expected to rise at a compound annual growth rate (CAGR) of 2.8% and reach $5.1 billion by 2014. The  chiral technology market is led by chiral synthesis products with more than 80% share.
    BCC Research report, Chiral Technology: Global Markets
  • The market for innovative biological therapies in cancer treatment will nearly double in the next 5 years, eventually exceeding $50 billion in the next 5 to 10 years. The biotherapy segment has recorded a 34.1% annual growth rate since 2004, and is forecast to almost double by 2014. Recent analysis reveals that biologic drugs will account for about 50% of the top 100 drugs in 2014.
    BCC Research report, Biological Therapies for Cancer: Technologies and Global Markets
  • A period of dynamic growth in the therapeutic vaccines market is expected with the rollout of some eight products before 2015, not only to treat cancer but to address nicotine addiction as well. The total worldwide market for therapeutic vaccines is expected to reach $137 million in 2010.  With increased product introductions, this market is expected to reach nearly $3.1 billion in 2014, a compound annual growth rate (CAGR) of more than 117%.
    BCC Research report, Therapeutic Vaccines: The Global Market
Published - Jul-2009| Analyst - Various Analysts| Code - BIO069A

Report Highlights


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report